Our Products News
-
Boehringer Ingelheim partners with Ribo to develop new treatments for people with liver diseasesBoehringer Ingelheim partners with Ribo to develop new treatments for people with liver diseasesJanuary 3, 2024 -
Ribo and Qilu Announce Licensing Agreement for siRNA Therapeutic Targeting PCSK9Ribo and Qilu Announce Licensing Agreement for siRNA Therapeutic Targeting PCSK9December 25, 2023 -
Ribo is to Present the Latest Research Data on Two Investigational siRNA Drugs under Development at EASL2023Ribo is to Present the Latest Research Data on Two Investigational siRNA Drugs under Development at EASL2023April 20, 2023 -
Suzhou Ribo announces the first siRNA-based FXI targeting anti-thrombotic agent (RBD4059) to receive HREC approval for first-in-human study in AustraliaSuzhou Ribo Life Science Co., Ltd. announces the first siRNA-based FXI targeting anti-thrombotic agent (RBD4059) to receive HREC approval for first-in-human study in Australia.February 9, 2023 -
Ribo Announces China CDE Approval of Clinical Trial Application of RBD7022 First-In-Human Clinical Trial in China for Treatment of Hyperlipidemia.Suzhou Ribo Life Science Co., Ltd. announced the company has received the approval from the CDE of the NMPA for the clinical trial application of its innovative PCKS9 targeting oligonucleotide drug product RBD7022 to conduct the First-In-Human clinical trial in China.September 20, 2022 -
Ribo Completed Two Phase II Clinical Studies in China for Evaluation of Effects of ISIS 449884 in Patients with Type 2 Diabetes Mellitus on Either Life-Style Intervention Only or Metformin Background TreatmentSuzhou Ribo Life Science Co., Ltd. has announced the successful completion of two phase II clinical trials of ISIS 449884, an antisense oligonucleotide（ASO）drug for treatment of Type 2 Diabetes Mellitus (T2DM).February 22, 2022